Sign In
Buy STRO
$23.57
-0.160 (-0.674%)
At Close: Jul 17, 2026
Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?
05:21am, Thursday, 04'th May 2023
Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric
Sutro: Too Little, Too Late For STRO-002, But Platform Is Interesting
01:17pm, Tuesday, 11'th Apr 2023
STRO is playing second fiddle to perpetually second fiddle player ImmunoGen in ovarian cancer. Although there are certain positive aspects to the molecule, I see little traction here.
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates
08:01pm, Thursday, 30'th Mar 2023
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock
Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
08:00am, Wednesday, 01'st Mar 2023
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 04'th Jan 2023
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 23'rd Nov 2022
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
07:00am, Thursday, 01'st Sep 2022
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma: Partnership Progress Warrants Exposure
01:05am, Tuesday, 16'th Aug 2022
Shares of Sutro Biopharma have lost one-third of their value over the past 3 years. Consolidation in the antibody drug conjugate space has made it an attractive area for drug development.
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates
07:34pm, Monday, 08'th Aug 2022
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 25.68% and 105.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
07:00am, Wednesday, 03'rd Aug 2022
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
07:00am, Tuesday, 12'th Jul 2022
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and n
Sutro Biopharma (STRO) Up 50% on Cancer Treatment Collaboration
01:52pm, Tuesday, 28'th Jun 2022
Sutro Biopharma (STRO) inks a partnership and licensing deal with Astellas Pharma to discover and develop iADCs for cancer patients not responding to existing therapies.
Sutro Biopharma Stock Surges On Cancer Treatment Pact
07:42am, Tuesday, 28'th Jun 2022
Astellas Pharma Inc (OTC: ALPMF) and Sutro Biopharma Inc (NASDAQ: STRO) announced a strategic collaboration and licensing agreement focused on the discovery and development of immunostimulatory
Sutro Biopharma to Participate in Upcoming Investor Conferences
07:00am, Thursday, 02'nd Jun 2022
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing c
Is a Surprise Coming for Sutro Biopharma (STRO) This Earnings Season?
11:17am, Thursday, 05'th May 2022
Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
